类风湿关节炎患者使用来氟米特后出现严重全血细胞减少症。

Severe pancytopenia after leflunomide in rheumatoid arthritis.

作者信息

Auer J, Hinterreiter M, Allinger S, Kirchgatterer A, Knoflach P

出版信息

Acta Med Austriaca. 2000;27(4):131-2. doi: 10.1046/j.1563-2571.2000.00034.x.

DOI:10.1046/j.1563-2571.2000.00034.x

Abstract

Leflunomide is a novel drug recently introduced for treatment of rheumatoid arthritis as a DMARD (disease-modifying antirheumatic drug). So far, leflunomide has not been associated with severe bone marrow toxicity and pancytopenia. We report of a 62-year-old woman with a 14-year history of rheumatoid arthritis with bone marrow toxicity and reversible pancytopenia developing after treatment with leflunomide.

摘要

来氟米特是一种最近被用于治疗类风湿关节炎的新型药物，作为一种改善病情抗风湿药（DMARD）。到目前为止，来氟米特尚未与严重的骨髓毒性和全血细胞减少相关联。我们报告了一名62岁女性，她有14年类风湿关节炎病史，在使用来氟米特治疗后出现骨髓毒性和可逆性全血细胞减少。